Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1992-09-10
1994-12-13
Stone, Jacqueline
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
424 9464, 424 858, 424 9463, 53038825, 53038826, A61K 3754, A61K 37547, A61K 3900, C07K 1528
Patent
active
053728122
ABSTRACT:
The present invention relates to a novel treatment for blood clots within a patient or myocardial infarction which comprises administering a hapten-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for blood clots within a patient or myocardial infarction comprising coadministrating the hapten-binding molecule of the invention together with a thrombolytic agent capable of either dissolving fibrin-platelet clots or inhibiting their formation. The therapy of the invention is capable of increasing clot lysis while minimizing fibrinogen breakdown and preventing the reocclusion of the affected coronary artery. The therapy of the present invention is capable of achieving this goal even in the absence of heparin and when the concentration of thrombolytic agent is lower than that required by other potential therapies.
REFERENCES:
patent: 4147765 (1979-04-01), Stephan et al.
patent: 4198335 (1980-04-01), Collen
patent: 4216291 (1980-08-01), Collen
patent: 4245040 (1981-01-01), Pilgeram
patent: 4273873 (1981-06-01), Sugitachi et al.
patent: 4346029 (1982-08-01), Collen
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4455290 (1984-06-01), Olexa et al.
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4474893 (1984-10-01), Reading
patent: 4545988 (1985-10-01), Nakayama et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4722903 (1988-02-01), Kudryk et al.
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4833085 (1989-05-01), Schaumann et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5116613 (1992-05-01), Haber et al.
Collen and Verstraete, ".alpha..sub.2 -Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy", Thrombosis Research 14:631-639 (1979).
Collen and Wiman, "Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma", Blood 53(2):313-324 (Feb. 1979).
Kane, "Fibrinolysis--A Review", Annals of Clinical and Laboratory Science 14(6):443-449 (1984).
Mudgett-Hunter et al., "Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies", Molecular Immunology 22(4):477-488 (1985).
Ouchi and Warren, "Detection of intravascular thrombi by means of I.sup.131 -labeled plasmin", Surgery 51(1):42-49 (Jan. 1962).
Agnelli et al., "The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits", Thrombosis and Haemostasis 63(2):204-207 (1990).
Agnelli et al., "A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits", Circulation 72(1):178-182 (1985).
Agnelli et al., "Sustained thrombolysis with DNA", Blood 66(2):399-401 (Aug. 1985).
Angles-Cano, E. R., "Tissue plasminogen activator determination with a fibrin-supported film", Chem. Abstracts 104:307-308, Abstract No. 144639d (1986).
Aoki, N. et al., "Fibrin-associated plasminogen activation in .alpha..sub.2 -plasmin inhibitor deficiency", Blood 62(5):1118-1122 (Nov. 1983).
Bode et al., "Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator", Circulation 81(6):1974-1980 (Jun. 1990).
Bode et al., "Antibody-directed urokinase: a specific fibrinolytic agent", Science 229:765-767 (Aug. 23, 1985).
Bode et al., "Thrombolysis by a fibrin-specific antibody Fab'urokinase conjugate", J. Mol. Cell Cardiol. 19:335-341 (1987).
Bode et al., "Antibody-directed fibrinolysis", J. Biol. Chem. 264(2):944-948 (Jan. 15, 1989).
Boulianne et al., "Production of functional chimaeric mouse/human antibody", Nature 312:643-646 (Dec. 13, 1984).
Branscomb et al., "Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator", Thrombosis and Haemostasis 64(2):260-266 (1990).
Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G.sub.1 fragments", Science 229:81-83 (Jul. 5, 1985).
Carrasquillo et al., "Radioimmunodetection of human melanoma with monoclonal antibodies and Fab fragments", Radioimaging and Radioimmunotherapy, Burchiol and Rhodes, Eds., Elsevier Science Publishing Co., Inc., pp. 357-368 (1983).
Charpie et al., "A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase", Biochemistry 29(27):6374-6378 (1990).
Collen et al., "Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis", J. Clin. Invest. 71:368-376 (Feb. 1983).
Collen et al., "Thrombolytic and pharmacokinetic properties of chimeric tissue-type ad urokinase-type plasminogen activators", Circulation 84(3):1216-1234 (Sep. 1991).
Collen et al., "Synergism of thrombolytic agents in vivo", Circulation 74(4):838-842 (Oct. 1986).
DeWood et al., "Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction", New England J. of Medicine 303(16):897-902 (Oct. 16, 1980).
Dorai et al., "The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes", J. Immunol. 139(12):4232-4241 (Dec. 15, 1987).
Duberstein, R., "Scientists develop new technique for producing bispecific monoclonals", Genetic Engineering News 6:22 (1986).
Emeis, J. J. and Verheijen, J. H., "Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor- and kringle one-domains", Arzneim.-Forsch./Drug Res. 42(3):358-362 (1992).
Fisher et al., "Isolation and characterizaton of the human tissue-type plasminogen activator structural gene including its 5' flanking region", J. Biol. Chem. 260(20):11223-11230 (Sep. 15, 1985).
Gardell et al., "Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits", Circulation 84(1):244-253 (Jul. 1991).
Haber, E. et al., "Antibody targeting as a thrombolytic strategy", Annals of the New York Academy of Sciences, pp. 365-381 (Dec. 1992).
Hessel et al., "Primary structure of human fibrinogen and fibrin", Eur. J. Biochem. 98:521-534 (1979).
Kudryk et al., "Specificity of a monoclonal antibody for the NH.sub.2 -terminal region of fibrin", Molec. Immunol. 21(1):89-94 (1984).
Laffel, G. L. and Braunwald, E., "A new strategy for the treatment of acute myocardial infarction (first of two parts)", New England J. of Medicine 311(11):710-717 (Sep. 13, 1984).
Hauranieh et al., "Monoclonal antibodies to human cross-linked fibrin",Fed. Proc. 44:1846, Abstract No. 8381 (1985).
Hui et al., "Immunodection of human fibrin using monoclonal antibody-64C5 in an extracorporeal chicken model", Thrombosis and Haemostasis 54(2):524-527 (1985).
Hui et al., "Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production", Hybridoma 5(3):215-222 (1986).
Hui et al., "Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen", Science 222:1129-1132 (Dec. 9, 1983).
Ito, R. K., "Fibrinolysis studies: fibrinogen-specific antibody as carriers for fibrinolytic agents", Fed. Proc. 44:1846, Abstract No. 8382 (1985).
Kabnick, K. S. and Housman, D. E., "Determinants that contribute to cytoplasmic stability of human c-fos and .beta.-globin mRNAs are located at several sites in each mRNA", Mol. Cell. Biol. 8(8):3244-3250 (Aug. 1988).
Kato et al., "A specific immunoassay system for hybrid type antigens", Chem. Abstracts 94:325, Abstract No. 61048j (1981).
Kimura, S. et al., "Acceleration of fibrinolysis by the N-terminal peptide of .alpha..sub.2 -plasmin inhibitor", Blood 66(1):157-160 (Jul. 1985).
Kudryk et al., "A monoclonal antibody with ability to distinguish between NH.sub.2 -terminal fragments derived from fibrinogen and fibrin", Molecular Immunology 20(11):1191-1200 (1983).
Laffel, G. L. and Braunwald, E., "A new strategy for the treatme
Haber Edgar
Matsueda Gary R.
Reed Guy L.
Stone Jacqueline
The General Hospital Corporation
LandOfFree
Composition and method for acceleration of clot lysis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for acceleration of clot lysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for acceleration of clot lysis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1191804